Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Compoundingcompoundingglp-1patient safety

USA Today Guides Patients on Vetting Compounded GLP-1 Sellers

Consumer piece outlines how to distinguish legitimate compounding providers from risky sources of weight-loss injectables.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 15 14:40 ETSource: USA Today

The wire

  1. 01USA Today published guidance on identifying legitimate compounded GLP-1 providers.
  2. 02Compounded semaglutide and tirzepatide sales continue despite safety and legality questions.
  3. 03Article does not report new regulatory action against specific sellers.

From the source

How to tell a legitimate compounded GLP-1 provider from a risky one

Read at news.google.com
Source URL https://news.google.com/rss/articles/CBMi5AFBVV95cUxQRGp3bVJ3Y3ZYSHJVZzFjYTZSZHRDUS12QWlKTWpTeVpmQlZ2VUtUY25BcUNrM1I0dnNkUzdfWmZIOVVmak11cDJSTmw5RVlCQ3lPYWdiT0lxOVJsZkZPZlVuSHMxYjBKeVFXWm5tcEw5NG1WQWpkYXg4NXlrRG1ITmV2eFl4aXI4aDFSVmk1V0x2Z2c2U0VrdHIzT0N6MFhFUVktSTFwUmxYTzgyUGR0VmRxYl9ZYTZUQnBTX3BVZ3hZVzdQQTBzYVl0VUNOaGJBNldnSHRaNkF0aFdhaGN0N2U4UVA?oc=5